120 related articles for article (PubMed ID: 31499585)
21. Rationale for selecting exfoliated bladder cell micronuclei as potential biomarkers for arsenic genotoxicity.
Smith AH; Hopenhayn-Rich C; Warner M; Biggs ML; Moore L; Smith MT
J Toxicol Environ Health; 1993; 40(2-3):223-34. PubMed ID: 8230298
[TBL] [Abstract][Full Text] [Related]
22. Elevated connexin 43 expression in arsenite-and cadmium-transformed human bladder cancer cells, tumor transplants and selected high grade human bladder cancers.
Zhang R; Wang L; Garrett SH; Sens DA; Dunlevy JR; Zhou XD; Somji S
Exp Toxicol Pathol; 2016 Oct; 68(9):479-491. PubMed ID: 27531258
[TBL] [Abstract][Full Text] [Related]
23. Promoter methylation of DNA damage repair (DDR) genes in human tumor entities:
Mijnes J; Veeck J; Gaisa NT; Burghardt E; de Ruijter TC; Gostek S; Dahl E; Pfister D; Schmid SC; Knüchel R; Rose M
Clin Epigenetics; 2018; 10():15. PubMed ID: 29445424
[TBL] [Abstract][Full Text] [Related]
24. Incidence of transitional cell carcinoma and arsenic in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in northeastern Taiwan.
Chiou HY; Chiou ST; Hsu YH; Chou YL; Tseng CH; Wei ML; Chen CJ
Am J Epidemiol; 2001 Mar; 153(5):411-8. PubMed ID: 11226969
[TBL] [Abstract][Full Text] [Related]
25. Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis.
Eblin KE; Bredfeldt TG; Buffington S; Gandolfi AJ
Toxicol Sci; 2007 Feb; 95(2):321-30. PubMed ID: 17093206
[TBL] [Abstract][Full Text] [Related]
26. SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
Chiang CY; Pan CC; Chang HY; Lai MD; Tzai TS; Tsai YS; Ling P; Liu HS; Lee BF; Cheng HL; Ho CL; Chen SH; Chow NH
Clin Cancer Res; 2015 Dec; 21(24):5601-11. PubMed ID: 26286913
[TBL] [Abstract][Full Text] [Related]
27. Low-to-Moderate Arsenic Exposure and Urothelial Tract Cancers with a Long Latent Period of Follow-Up in an Arseniasis Area.
Liao PJ; Lee CH; Wang SL; Chiou HY; Chen CJ; Seak CJ; Wu IW; Hsu KH
J Epidemiol Glob Health; 2023 Dec; 13(4):807-815. PubMed ID: 37725327
[TBL] [Abstract][Full Text] [Related]
28. Expression of bone morphogenetic protein-10 (BMP10) in human urothelial cancer of the bladder and its effects on the aggressiveness of bladder cancer cells in vitro.
Zhang N; Ye L; Wu L; Deng X; Yang Y; Jiang WG
Anticancer Res; 2013 May; 33(5):1917-25. PubMed ID: 23645739
[TBL] [Abstract][Full Text] [Related]
29. Association between Arsenic Level, Gene Expression in Asian Population, and In Vitro Carcinogenic Bladder Tumor.
Singhal S; Ruprecht NA; Sens D; Tavakolian K; Gardner KL; Singhal SK
Oxid Med Cell Longev; 2022; 2022():3459855. PubMed ID: 35039759
[TBL] [Abstract][Full Text] [Related]
30. Melatonin-mediated downregulation of ZNF746 suppresses bladder tumorigenesis mainly through inhibiting the AKT-MMP-9 signaling pathway.
Chen YT; Yang CC; Shao PL; Huang CR; Yip HK
J Pineal Res; 2019 Jan; 66(1):e12536. PubMed ID: 30372570
[TBL] [Abstract][Full Text] [Related]
31. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study.
Huang YK; Huang YL; Hsueh YM; Yang MH; Wu MM; Chen SY; Hsu LI; Chen CJ
Cancer Causes Control; 2008 Oct; 19(8):829-39. PubMed ID: 18351295
[TBL] [Abstract][Full Text] [Related]
32. Orally administered nicotine effects on rat urinary bladder proliferation and carcinogenesis.
Suzuki S; Cohen SM; Arnold LL; Kato H; Fuji S; Pennington KL; Nagayasu Y; Naiki-Ito A; Yamashita Y; Takahashi S
Toxicology; 2018 Apr; 398-399():31-40. PubMed ID: 29501575
[TBL] [Abstract][Full Text] [Related]
33. Characterization of Tumor Blood Vasculature Expression of Human Invasive Bladder Cancer by Laser Capture Microdissection and Transcriptional Profiling.
Roudnicky F; Poyet C; Buser L; Saba K; Wild P; Otto VI; Detmar M
Am J Pathol; 2020 Sep; 190(9):1960-1970. PubMed ID: 32585158
[TBL] [Abstract][Full Text] [Related]
34. Trace metal quantification in bladder biopsies from tumoral lesions of Tunisian cancer and controls subjects.
Feki-Tounsi M; Olmedo P; Gil F; Mhiri MN; Rebai A; Hamza-Chaffai A
Environ Sci Pollut Res Int; 2014 Oct; 21(19):11433-8. PubMed ID: 24903250
[TBL] [Abstract][Full Text] [Related]
35. Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors.
Jeppesen DK; Nawrocki A; Jensen SG; Thorsen K; Whitehead B; Howard KA; Dyrskjøt L; Ørntoft TF; Larsen MR; Ostenfeld MS
Proteomics; 2014 Mar; 14(6):699-712. PubMed ID: 24376083
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathological characteristics and survival outcome of arsenic related bladder cancer in taiwan.
Chen CH; Chiou HY; Hsueh YM; Chen CJ; Yu HJ; Pu YS
J Urol; 2009 Feb; 181(2):547-52; discussion 553. PubMed ID: 19084863
[TBL] [Abstract][Full Text] [Related]
37. Arsenic methylation and bladder cancer risk in Taiwan.
Chen YC; Su HJ; Guo YL; Hsueh YM; Smith TJ; Ryan LM; Lee MS; Christiani DC
Cancer Causes Control; 2003 May; 14(4):303-10. PubMed ID: 12846360
[TBL] [Abstract][Full Text] [Related]
38. Decreased urinary beta-defensin-1 expression as a biomarker of response to arsenic.
Hegedus CM; Skibola CF; Warner M; Skibola DR; Alexander D; Lim S; Dangleben NL; Zhang L; Clark M; Pfeiffer RM; Steinmaus C; Smith AH; Smith MT; Moore LE
Toxicol Sci; 2008 Nov; 106(1):74-82. PubMed ID: 18511430
[TBL] [Abstract][Full Text] [Related]
39. Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data.
Xu Y; Wu G; Li J; Li J; Ruan N; Ma L; Han X; Wei Y; Li L; Zhang H; Chen Y; Xia Q
Biomed Res Int; 2020; 2020():8283401. PubMed ID: 32047816
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of the bladder cancer marker, BLCA-4.
Van Le TS; Myers J; Konety BR; Barder T; Getzenberg RH
Clin Cancer Res; 2004 Feb; 10(4):1384-91. PubMed ID: 14977841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
